Proteinase-activated receptor-2 (PAR 2 ) is widely expressed in the respiratory tract and is an integral component of the host antimicrobial defence system. The principal aim of this study was to investigate the influence of a PAR 2 -activating peptide 
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Specimens were subsequently mounted onto support studs, coated with a gold/paladium mix of <15nm thickness and examined under a Philips XL30 scanning electron microscope. Photomicrographs shown are representative of at least 3 independent studies from 3 mice.
Lung function recording.
To determine the effect of SLIGRL on IAV-induced airways hyperresponsiveness, inoculated mice were examined on day 4 postinoculation using in vivo lung function recording systems. Briefly, mice were anaesthetised (urethane, 1.5 g/kg, i.p.) and cannulae placed in the trachea (to measure airflow) and jugular vein (for drug administration). Spontaneous breathing was stopped by an intravenous injection of pancuronium bromide (0.4 mg/kg and 0.2 mg/kg each 30 min thereafter) and mice ventilated (tidal volume 8 ml/kg at 150 breathes/min, SAR-830 Ventilator). Breath-to-breath measurements of airway resistance (R L ) and dynamic compliance (Cdyn) were recorded (PMS800, Mumed).
Tracheal flow was measured over the tracheal cannula (Fleisch pneumotachograph) and transpulmonary pressure measured with a differential pressure transducer, one end being connected to the outlet of the tracheal cannula, the other to a water-filled cannula inserted in the esophagus. A self-regulating heating pad (Fine Science Tools) was used to maintain core temperature at 37 o C. A bronchoconstrictor stimulus, methacholine (dose-range 50-1600 g/kg, i.v.) was administered as a bolus dose at 5 minute intervals to determine airways responsiveness. Prior to each methacholine challenge, lungs were hyperinflated once (by delivering twice tidal volume) to prevent and reverse atelectasis.
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Isometric tension recording studies.
The functionality of PAR 2 in PAR 2 -deficient and wild-type mice was determined using an isometric tension recording assay. Tracheal smooth muscle segments were suspended under a resting tension of 0.5 g in organ baths containing 2 ml of Krebs bicarbonate solution, maintained at and supramaximal (10 M) concentrations of carbachol, and washed and rested.
Preparations were precontracted with carbachol to (60-70% contraction maximum) and upon reaching a plateau level of contracture, a single concentration of peptide (SLIGRL, LSIGRL, IGRL and 2-furoyl-LIGRL) was added and the relaxation response recorded. Preparations were washed and allowed to re-equilibrate for 15 min, and the process repeated using another peptide.
Tracheal Explant Media. Isolated mouse tracheas were maintained by a continuous flow (100uL/min) of RPMI 1640 (Sigma) supplemented with Hepes (20mM), FBS (2%), Amphotericin β (2.5ug/ml), GlutaMAX ™ (2mM) and Gentamycin (50ug/ml), supplied by Gibco. Prior to exposure with IAV, tracheas were allowed to equilibrate for one hour at 37°C with continuous flow of complete medium (cRPMI). Monolayers were washed (to remove non-adherent erythrocytes), and the number of adherent erythrocytes per microscopic field counted, with at least 3 different, randomised fields counted to provide a well value.
The influence of SLIGRL and related peptides on the pathogenicity of IAV was determined using MDCK cell cultures. MDCK cells were harvested from T-25 flasks at P5 -P7, resuspended in DMEM (4.5 g/L glucose, 100mg/L pyruvate supplemented with 5% FCS, 2mM GlutaMAX ™ , 100 IU/ml penicillin, 100 g/ml streptomycin, 2.5 g/ml amphotericin B (Gibco)), plated into 96 well tissue culture plates at 10,000 cells/well and maintained in a humidified CO 2 incubator at 37˚C. Figure   2F ), compared to VEHICLE mice ( Figure 2D ). It is not clear whether these subtle differences in epithelial morphology between VIRUS+SLIGRL mice ( Figure 2F ) and VEHICLE mice ( Figure 2D ) were due to the actions of SLIGRL and/or IAV.
Haematoxylin & eosin stained tracheal and lung sections obtained from VIRUS mice exhibited characteristic lymphocytic peribronchitis, iatrogenic atelectasis and intraluminal cellular debris on day 4 and 8. In contrast, tracheal and lung sections from VIRUS + SLIGRL mice were indistinguishable from VEHICLE mice and were devoid of any signs of IAV-induced histopathology (data not shown).
JPET #196485 Dose-response relationship for SLIGRL and structural analogues. The dose of SLIGRL that suppressed influenza A virus-induced increases in BAL neutrophil number by 50% was 10 g/mouse ( Figure 3A) . Surprisingly, doseresponse studies revealed that the partially scrambled peptide sequence LSIGRL produced the same maximal effect as SLIGRL (full suppression of virus-induced increases in BAL neutrophil number), and was only four-fold less potent than SLIGRL (IC 50 value of 40 g/mouse, Figure 3A ). Of particular interest, 2-furoyl-LIGRL which is typically 20-100 fold more potent than SLIGRL as an activator of PAR 2 (Kawabata et al., 2004) , was inactive up to doses of 30 g/mouse, and IGRL which is not known to activate PAR 2 was 2.5 fold more potent than SLIGRL (IC 50 value of 4 g/mouse, Figure 3A ). These data are not consistent with the inhibitory effects of SLIGRL on IAV infection being mediated solely through activation of PAR 2 , and were the trigger for further studies using PAR 2 -/-mice.
Inhibitory effects of SLIGRL in PAR 2 +/+ and PAR 2 -/-mice. IAV induced a similar increase in pulmonary leukocytes in PAR 2 +/+ and PAR 2 -/-mice ( Figure 3B ). Of particular interest, SLIGRL (20 g/mouse, i.n.) inhibited IAV-induced pulmonary inflammation in both PAR 2 +/+ and PAR 2 -/-mice ( Figure 3B ), indicating that SLIGRL was exerting anti-IAV effects via a PAR 2 -independent pathway. Confirmation of the lack of functional PAR 2 in PAR 2 -/-mice was obtained from isometric tension recording studies. As shown in Figure 3C , the well-established PAR 2 -mediated smooth muscle relaxant actions of SLIGRL and 2-furoyl-LIGRL in pre-contracted mouse tracheal segments (Lan et al., 2000 (Lan et al., , 2001 were present in PAR 2 +/+ mice but absent in PAR 2 -/-mice. As expected, the partially scrambled peptide sequence Secondly, and even more compelling, were the findings that SLIGRL inhibited IAV-induced recruitment of pulmonary leukocytes in mice that lacked PAR 2 ( Figure   3B ), and inhibited the proliferation of IAV in mouse isolated tracheal segments obtained from PAR 2 -deficient mice ( Figure 4C ). The absence of functional PAR 2 in the trachea of PAR 2 -/-mice was confirmed in isometric tension recording studies, which showed that SLIGRL was inactive in tracheal smooth muscle preparations obtained from PAR 2 -/-mice, but produced dose-dependent relaxation in wild-type, PAR 2 +/+ mice (Lan et al., 2000 (Lan et al., , 2001 . Together, the use of PAR 2 -/-mice and structure activity analyses of PAR-activating peptides (McGuire et al., 2002) powerfully demonstrates the anti-IAV actions of SLIGRL are PAR 2 -independent.
In light of our unexpected findings that SLIGRL inhibits IAV infection via PAR 2 -independent processes, a secondary aim of the study was to investigate how Attachment of the virus to the cell surface is followed by the endocytosis of virus, the fusion of viral and endosomal membranes, the release, transcription and translation of the viral genome, and the packaging and release of progeny virions (Muller et al., 2012) . This process of IAV replication depends on dozens of host factors, and the majority of conventional antiviral compounds studied to date act via cellular pathways to alter the ability of the virus to propagate (Guo et al., 2006; Magden et al., 2005; McNicholl et al., 2001; Takeda et al., 2002) . However, it is unlikely that SLIGRL directly inhibits IAV propagation pathways because it did not inhibit IAV replication in either chorioallantoic membranes or MDCK cells. These latter findings contrast with recent reports that PAR 2 activating peptides decreased progeny influenza A virus titers in isolated human monocytes (Feld et al., 2008) to IAV for 15 minutes, washed and 48 hours later processed for immunoreactive staining for IAV. Some tracheal segments (C) were exposed to IAV alone, whereas others were also exposed to SLIGRL either (D) at the same time as IAV exposure or (E) before IAV exposure. Bar = 100 m. In (E), tracheal segments were exposed to SLIGRL for 15 minutes, washed with saline for 5 minutes and then exposed to IAV. This article has not been copyedited and formatted. The final version may differ from this version.
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